FDA advisory panel backs broader compounding of six peptide drugs despite limited safety data

An FDA advisory panel reviewed seven peptide therapies and voted to ease access to six of them. The recommendation would let compounding pharmacies manufacture these peptides, expanding how they can be obtained.

The votes were narrow and contested, reflecting concerns that the safety and efficacy data for many of the peptides are limited. If the panel's advice becomes policy, the drugs could be used for a broader range of conditions than currently approved.

Proponents argue the change could improve patient access to peptide treatments, while critics warn it may reduce oversight and increase safety risks. The panel’s suggestions are advisory; the FDA will decide whether to adopt them into formal regulations.

The outcome highlights ongoing regulatory debate over how to balance innovation, access, and patient protection in the growing peptide market.